

Engagement Report for Clinical Commissioning Policies

Unique Reference Number	A01X07
Policy Title	Continuous aztreonam lysine for cystic fibrosis (all ages)
Accountable Commissioner	Sue Sawyer
Clinical Reference Group	Cystic fibrosis
Which stakeholders were contacted to be involved in policy development?	Cystic fibrosis CRG membership and all registered stakeholders
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment
Explain reason if there is any difference from previous question	Not applicable

FOR PUBLIC CONSULTATION ONLY

<p>Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?</p>	
<p>How have the stakeholders been involved? What engagement methods have been used?</p>	<p>The draft policy was circulated to the full membership of the CRG and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be.</p> <p>Two responses were received; one from a CRG-registered stakeholder and one from the Cystic Fibrosis (CF) CRG. The CF CRG acknowledged that all relevant published evidence have been reviewed but requested that unpublished evidence be considered as well. While noting the strength of clinical conviction, the PWG concluded that they could not consider unpublished evidence. The CRG also emphasised the clinical use of continuous aztreonam, it being used in 51 patients in large adult centres across England. The CRG-registered stakeholder, a pharmaceutical company, provided additional patient numbers to consider, requested additional evidence to be considered and identified additional stakeholders to be consulted. The clinical evidence review team reviewed the study requested as part of the evidence review, but not included within the summary as the findings relating to continuous use of Aztreonam for P. Aeruginosa were incidental only in nature.</p>
<p>What has happened or changed as a result of their input?</p>	<p>Stakeholders were invited to comments. Minor changes were made to the policy proposition to update the estimate of patients that could be affected. No changes were made to the evidence review. Additional identified stakeholders will be invited to comment as part of the public consultation.</p>
<p>How are stakeholders being kept informed of progress with policy development as a result of their input?</p>	<p>This engagement report, along with the updated policy proposition will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.</p>
<p>What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?</p>	<p>Public consultation for a period of 30 days as supported by stakeholders</p>